Greetings rheumatology friends! The next session of #RheumJC will be Thursday, May 5, 2016, where we will be discussing secukinumab, an anti-interleukin–17A monoclonal antibody that was recently FDA approved for the treatment of psoriatic arthritis. The article we’ll be discussing was published in October 2015 in the New England Journal of Medicine and is titled Secukinumab Inhibition of Interleukin–17A in Patients with Psoriatic Arthritis. We again expect a lively discussion about this new treatment option.
This article is open access and can found at this link: http://www.nejm.org/doi/full/10.1056/NEJMoa1412679
A direct link to the PDF is available here: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1412679
We will again have two one-hour sessions, the first at 9pm GMT (4pm EST) and the second at 3am GMT (10pm EST).
If you are new to using Twitter, take a look at our Intro to Twitter page.
If you are participating in a Twitter journal club chat for the first time, please read our Getting Started Guide to get some tips on how to make the most of this session and not get too bogged down. Some additional pointers:
- Please remember to try to stay on topic whenever possible.
- Be polite and courteous.
- Do not violate HIPAA.
As always, we welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@gmail.com.